Effect of a buffer mixture system on the activity of lipases during immobilization process

2010 ◽  
Vol 101 (1) ◽  
pp. S66-S70 ◽  
Author(s):  
Jong Ho Lee ◽  
Sung Bong Kim ◽  
Chulhwan Park ◽  
Seung Wook Kim
2020 ◽  
Vol 1412 ◽  
pp. 062005
Author(s):  
Florian Schäfer ◽  
Hideki Konishi ◽  
Adrien Bouscal ◽  
Tomoya Yagami ◽  
Matthew D Frye ◽  
...  

2008 ◽  
Vol 41 (6) ◽  
pp. 062002 ◽  
Author(s):  
SeungYeon Jeong ◽  
DongWoo Kim ◽  
KungWon Rhie ◽  
MunPyo Hong ◽  
Satyendra Kumar ◽  
...  

Pathogens ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 219 ◽  
Author(s):  
Ines Sifaoui ◽  
Eulalia Capote Yanes ◽  
María Reyes-Batlle ◽  
Rubén L. Rodríguez-Expósito ◽  
José E. Piñero ◽  
...  

The establishment of an effective therapeutic agent against Acanthamoeba keratitis (AK), remains until present, an issue to be solved due to the existence of a cyst stage in the life cycle of Acanthamoeba. Moreover, the effectiveness of the current standard therapeutic agents varies depending on the tested Acanthamoeba strains and its resistance pattern. In the present study, two 10-point augmented simplex-centroid designs were used to formulate a three-component mixture system using water, atorvastatin, and Diclofenaco-lepori or Optiben. The amoebicidal effects and in vitro-induced toxicity in a eukaryotic cell line were determined for all experiments. The optimal mixture to inhibit the parasite without inducing toxicity was established in the first plan as 30% Optiben, 63.5% atorvastatin, and 3.1% water. As for the second experimental design, the optimal mixture to inhibit Acanthamoeba with lower toxicity effect was composed of 17.6% Diclofenaco-lepori and 82.4% atorvastatin.


1985 ◽  
Vol 68 (5) ◽  
pp. 1051-1055
Author(s):  
Richard D Thompson

Abstract A liquid chromatographic (LC) method for the determination of colchicine in pharmaceutical dosage forms and the bulk drug was evaluated in an interlaboratory study which included 13 participating laboratories. The method involves extraction (or dissolution) of the active ingredient with methanol-water (1 + 1), followed by filtration of the extract and reverse phase LC using an octy lsilane bonded phase column and UV detection at 254 nm. The mobile phase consists of a methanolphosphate buffer mixture (pH = 5.5). Three commercial tablet formulations (0.5-0.6 mg colchicine/tablet), 1 synthetic injectable preparation (0.510 mg colchicine/mL), and 1 bulk drug sample were assayed in duplicate by the proposed method. The reproducibility and repeatability standard deviations based on nonpooled results for each sample ranged from 0.0062 mg/mL to 0.0147 mg/tablet and from 0.0037 mg/ mL to 0.0127 mg/tablet, respectively; the corresponding coefficients of variation ranged from 1.21 to 2.54% and from 0.73 to 2.19%, respectively. The mean recovery from the synthetic injectable formulation was 100.0%. The method has been adopted official first action


1987 ◽  
Vol 23 (2) ◽  
pp. 253-261 ◽  
Author(s):  
W. Nighan ◽  
R. Sauerbrey ◽  
Yunping Zhu ◽  
F. Tittel ◽  
W. Wilson

Sign in / Sign up

Export Citation Format

Share Document